Whitehawk expands ADC pipeline with new option agreement for CPT113 linker-payload

Whitehawk Therapeutics entered into an option agreement with Hangzhou DAC for access to CPT113 for up to five additional ADC programs, with anticipated IND submissions over the next 12-24 months. The expansion validates the company's CPT113 linker-payload technology platform and demonstrates clinical momentum with HWK-007 and HWK-016 currently enrolling.